BRPI0810161A2 - Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto - Google Patents

Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto

Info

Publication number: BRPI0810161A2
Authority: BR; Brazil
Prior art keywords: compound; pharmaceutical; pharmaceutical composition; pharmaceutical preparation; preparation
Prior art date: 2007-04-12

Application number

Other languages

English (en)

Inventor

Hakan V Wikstroem

Original Assignee

Nsab Af Neurosearch Sweden Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-12

Filing date

2008-04-11

Publication date

2014-12-30

2008-04-11 Application filed by Nsab Af Neurosearch Sweden Ab filed Critical Nsab Af Neurosearch Sweden Ab

2014-12-30 Publication of BRPI0810161A2 publication Critical patent/BRPI0810161A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Molecular Biology (AREA)
Child & Adolescent Psychology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Anesthesiology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BRPI0810161 2007-04-12 2008-04-11 Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto BRPI0810161A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0700893		2007-04-12
PCT/SE2008/050414 WO2008127188A1 (en)	2007-04-12	2008-04-11	N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles

Publications (1)

Publication Number	Publication Date
BRPI0810161A2 true BRPI0810161A2 (pt)	2014-12-30

Family

ID=39864178

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0810161 BRPI0810161A2 (pt)	2007-04-12	2008-04-11	Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto

Country Status (19)

Country	Link
US (1)	US9139525B2 (pt)
EP (1)	EP2146961B1 (pt)
JP (1)	JP5393654B2 (pt)
CN (1)	CN101711236B (pt)
AU (1)	AU2008239841B2 (pt)
BR (1)	BRPI0810161A2 (pt)
CA (1)	CA2683719C (pt)
CY (1)	CY1115337T1 (pt)
DK (1)	DK2146961T3 (pt)
ES (1)	ES2458592T3 (pt)
HR (1)	HRP20140380T1 (pt)
IL (1)	IL201401A (pt)
MX (1)	MX2009011020A (pt)
NZ (1)	NZ580856A (pt)
PL (1)	PL2146961T3 (pt)
PT (1)	PT2146961E (pt)
RU (1)	RU2470013C2 (pt)
SI (1)	SI2146961T1 (pt)
WO (1)	WO2008127188A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE46117E1 (en)	1999-12-22	2016-08-23	Teva Pharmaceuticals International Gmbh	Modulators of dopamine neurotransmission
KR101660936B1 (ko) *	2008-11-24	2016-10-05	인터그레이티브 리서치 래버러토리즈 스웨덴 에이비	피질 카테콜아민성 신경전달의 조절자로서의 ３-페닐-３-메톡시피롤리딘 유도체
WO2011107583A1 (en)	2010-03-04	2011-09-09	Nsab, Filial Af Neurosearch Sweden Ab, Sverige	Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EP2611759A1 (en)	2010-09-03	2013-07-10	Ivax International Gmbh	Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9018202B2 (en) *	2010-12-03	2015-04-28	Allergan, Inc.	Methods for treating diseases of the retina
JP6189299B2 (ja)	2011-09-07	2017-08-30	テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー	プリドピジン塩酸塩の新規な多形形態
EP2787997A4 (en)	2011-12-08	2015-05-27	Ivax Int Gmbh	HYDROBROMIDE SALT OF PRIDOPIDINE
JP6177875B2 (ja)	2012-04-04	2017-08-09	テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｔｅｒｎａｔｉｏｎａｌＧｍｂＨ	併用療法のための医薬組成物
US11090297B2 (en)	2013-06-21	2021-08-17	Prilenia Neurotherapeutics Ltd.	Pridopidine for treating huntington's disease
WO2014205229A1 (en)	2013-06-21	2014-12-24	IVAX International GmbH	Use of high dose pridopidine for treating huntington's disease
TW201613859A (en) *	2014-06-30	2016-04-16	Teva Pharma	Analogs of PRIDOPIDINE, their preparation and use
JP2018505147A (ja)	2014-12-22	2018-02-22	テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー	プリドピジンのｌ−酒石酸塩
US11471449B2 (en)	2015-02-25	2022-10-18	Prilenia Neurotherapeutics Ltd.	Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
JP6887952B2 (ja)	2015-02-25	2021-06-16	プリレニアニューロセラピューティクスリミテッド	認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
AR105434A1 (es)	2015-07-22	2017-10-04	Teva Pharmaceuticals Int Gmbh	Proceso para preparar pridopidina
WO2017147366A1 (en)	2016-02-24	2017-08-31	Teva Pharmaceuticals International Gmbh	Treatment of neurodegenerative eye disease using pridopidine
AU2017315781B2 (en)	2016-08-24	2021-01-28	Prilenia Neurotherapeutics Ltd	Use of pridopidine for treating dystonias
AU2017315783C1 (en)	2016-08-24	2020-12-24	Prilenia Neurotherapeutics Ltd	Use of pridopidine for treating a subject with early stage huntington disease
US12102627B2 (en)	2016-09-16	2024-10-01	Prilenia Neurotherapeutics Ltd.	Use of pridopidine for treating rett syndrome
WO2018136600A1 (en)	2017-01-20	2018-07-26	Teva Pharmaceuticals International Gmbh	Use of pridopidine for the treatment of fragile x syndrome
DK3668509T3 (da)	2017-08-14	2023-02-20	Prilenia Neurotherapeutics Ltd	Fremgangsmåde til behandling af amyotrofisk lateralsklerose med pridopidin
BR112020004045A2 (pt)	2017-08-30	2020-09-01	Prilenia Neurotherapeutics Ltd.	formas de dosagem de elevada concentração de pridopidina
MX2020002645A (es)	2017-09-08	2021-06-10	Prilenia Neurotherapeutics Ltd	Pridopidina para el tratamiento de las discinesias inducidas por fármacos.
US12036213B2 (en)	2017-09-08	2024-07-16	Prilenia Neurotherapeutics Ltd.	Pridopidine for treating drug induced dyskinesias
CN116472043A (zh) *	2020-10-20	2023-07-21	普瑞尼亚神经治疗有限公司	普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1217296A (en)	1917-01-11	1917-02-27	Lewis A Peckham	Shock-absorber.
US2813097A (en)	1955-08-16	1957-11-12	Upjohn Co	3-hydroxy-n-methylmorphinan-n-oxide
US2813098A (en)	1955-08-16	1957-11-12	Upjohn Co	3-methoxy-n-methylmorphinan n-oxide
US3131185A (en)	1959-03-18	1964-04-28	Orsymonde	Nicotinic esters of hydroxyl derivatives of the phenanthrenic alkaloids of opium, and process for the preparation of these esters
BE638369A (pt)	1962-10-10
CH481123A (de)	1966-09-21	1969-11-15	Geigy Ag J R	Verfahren zur Herstellung von neuen, kondensierten heterocyclischen Verbindungen
AU658134B2 (en)	1989-12-28	1995-04-06	Virginia Commonwealth University	Sigma receptor ligands and the use thereof
ATE201669T1 (de) *	1991-04-17	2001-06-15	Upjohn Co	Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
PT100639A (pt)	1991-06-27	1993-09-30	Univ Virginia Commonwealth	Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
IL112099A (en) *	1993-12-23	1999-07-14	Ortho Pharma Corp	N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
CA2144669A1 (en)	1994-03-29	1995-09-30	Kozo Akasaka	Biphenyl derivatives
AU757870B2 (en) *	1998-11-23	2003-03-06	Sepracor, Inc.	Pharmaceutical compositions containing olanzapine-N-oxide
SE9904724D0 (sv) *	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission I
SE9904723D0 (sv) *	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission II
SE0200301D0 (sv) *	2002-02-01	2002-02-01	Axon Biochemicals Bv	Thio-carbostyril derivative
MXPA06013941A (es) *	2004-06-08	2007-12-10	Neurosearch Sweden Ab	Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
NZ552411A (en)	2004-06-08	2010-04-30	Nsab Af Neurosearch Sweden Ab	New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
CA2576530A1 (en) *	2004-08-11	2006-02-23	Donald L. Barbeau	Noncardiotoxic pharmaceutical compounds
KR101319235B1 (ko) *	2004-10-13	2013-10-16	아이백스 인터내셔널 게엠베하	4-(3-메탄설폰일페닐)-1-ｎ-프로필-피페리딘의 합성 공정
DK1919883T3 (da) *	2005-08-22	2009-04-14	Solvay Pharm Bv	N-oxider som profarmakoner fra piperazin- og piperidinderivater
SE529246C2 (sv) *	2005-10-13	2007-06-12	Neurosearch Sweden Ab	Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
AU2007247251B2 (en)	2006-05-02	2011-11-03	Solvay Pharmaceuticals B.V.	N-oxides of pyridylmethylpiperazine and -piperidine derivatives
WO2011107583A1 (en) *	2010-03-04	2011-09-09	Nsab, Filial Af Neurosearch Sweden Ab, Sverige	Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20130203886A1 (en) *	2010-03-05	2013-08-08	Nileshkumar Prakash Kukalyekar	Process for the production of an uhmwpe article
EP2611759A1 (en) *	2010-09-03	2013-07-10	Ivax International Gmbh	Deuterated analogs of pridopidine useful as dopaminergic stabilizers
JP6189299B2 (ja)	2011-09-07	2017-08-30	テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー	プリドピジン塩酸塩の新規な多形形態
EP2787997A4 (en) *	2011-12-08	2015-05-27	Ivax Int Gmbh	HYDROBROMIDE SALT OF PRIDOPIDINE
JP6177875B2 (ja) *	2012-04-04	2017-08-09	テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｔｅｒｎａｔｉｏｎａｌＧｍｂＨ	併用療法のための医薬組成物
US20140088145A1 (en) *	2012-09-27	2014-03-27	Teva Pharmaceutical Industries, Ltd.	Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
AU2013323131A1 (en) *	2012-09-27	2015-05-07	Teva Pharmaceutical Industries Ltd.	Laquinimod and pridopidine for treating neurodegenerative disorders

2008
- 2008-04-11 BR BRPI0810161 patent/BRPI0810161A2/pt not_active IP Right Cessation
- 2008-04-11 AU AU2008239841A patent/AU2008239841B2/en not_active Ceased
- 2008-04-11 CA CA2683719A patent/CA2683719C/en not_active Expired - Fee Related
- 2008-04-11 EP EP20080741904 patent/EP2146961B1/en not_active Not-in-force
- 2008-04-11 MX MX2009011020A patent/MX2009011020A/es unknown
- 2008-04-11 CN CN2008800175988A patent/CN101711236B/zh not_active Expired - Fee Related
- 2008-04-11 JP JP2010502976A patent/JP5393654B2/ja not_active Expired - Fee Related
- 2008-04-11 ES ES08741904T patent/ES2458592T3/es active Active
- 2008-04-11 RU RU2009141300/04A patent/RU2470013C2/ru not_active IP Right Cessation
- 2008-04-11 PL PL08741904T patent/PL2146961T3/pl unknown
- 2008-04-11 NZ NZ580856A patent/NZ580856A/en unknown
- 2008-04-11 US US12/595,472 patent/US9139525B2/en active Active
- 2008-04-11 PT PT08741904T patent/PT2146961E/pt unknown
- 2008-04-11 SI SI200831188T patent/SI2146961T1/sl unknown
- 2008-04-11 WO PCT/SE2008/050414 patent/WO2008127188A1/en active Application Filing
- 2008-04-11 DK DK08741904T patent/DK2146961T3/da active
2009
- 2009-10-11 IL IL201401A patent/IL201401A/en not_active IP Right Cessation
2014
- 2014-04-25 CY CY20141100304T patent/CY1115337T1/el unknown
- 2014-04-25 HR HRP20140380AT patent/HRP20140380T1/hr unknown

Also Published As

Publication number	Publication date
CA2683719C (en)	2015-07-14
US9139525B2 (en)	2015-09-22
JP5393654B2 (ja)	2014-01-22
PT2146961E (pt)	2014-04-30
CN101711236B (zh)	2012-10-31
CY1115337T1 (el)	2017-01-04
WO2008127188A1 (en)	2008-10-23
NZ580856A (en)	2011-11-25
MX2009011020A (es)	2009-10-30
EP2146961A1 (en)	2010-01-27
CN101711236A (zh)	2010-05-19
IL201401A (en)	2015-10-29
SI2146961T1 (sl)	2014-08-29
EP2146961B1 (en)	2014-01-29
US20100105736A1 (en)	2010-04-29
CA2683719A1 (en)	2008-10-23
DK2146961T3 (da)	2014-04-28
IL201401A0 (en)	2010-05-31
HRP20140380T1 (hr)	2014-08-15
JP2010523651A (ja)	2010-07-15
PL2146961T3 (pl)	2014-09-30
AU2008239841A1 (en)	2008-10-23
EP2146961A4 (en)	2011-08-03
AU2008239841B2 (en)	2013-07-18
RU2009141300A (ru)	2011-05-20
RU2470013C2 (ru)	2012-12-20
ES2458592T3 (es)	2014-05-06

Publication	Publication Date	Title
BRPI0810161A2 (pt)	2014-12-30	Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0810696A2 (pt)	2014-10-21	Composto, composição farmacêutica, e, uso de um composto
BRPI0919942A2 (pt)	2014-12-23	Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt)	2017-05-23	composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt)	2015-12-29	composto, composição farmacêutica, e, uso de um composto
BRPI0815709A2 (pt)	2017-06-13	composro, composição farmacêutica, e, uso de um composto.
BRPI0921879A2 (pt)	2018-10-16	composto, composição farmacêutica , e, uso de um composto
BRPI1008793A2 (pt)	2016-03-08	composto, uso de um composto, e, composição farmacêutica
BRPI1016219A2 (pt)	2016-04-26	composto, composição farmacêutica, e, uso de um composto
BRPI0917579A2 (pt)	2016-10-11	composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0810019A2 (pt)	2014-10-14	Composto, composição farmacêutica, e, uso de um composto
BRPI0821115A2 (pt)	2015-06-16	Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0716171A2 (pt)	2013-09-17	composto, composiÇço farmacÊutica e uso de um composto.
BRPI0609802A2 (pt)	2017-05-02	composto, composição farmacêutica e uso de um composto
BRPI0819696A2 (pt)	2015-06-16	Compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
BRPI1007018A2 (pt)	2016-03-29	composto, composição farmacêutica, e , uso de um composto.
BRPI0812942A2 (pt)	2014-12-16	Composto, composição farmacêutica e uso de um composto
BRPI1008906A2 (pt)	2016-03-15	composto, composição farmacêutica, e, uso de um composto.
BRPI0906937A2 (pt)	2016-04-19	composto, composição farmacêutica, e, uso de um composto
BRPI0818193A2 (pt)	2017-12-12	composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
BRPI0917001A2 (pt)	2016-02-16	composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0716698A2 (pt)	2014-02-25	Composto, composição farmacêutica e uso de um composto
BR112013008259A2 (pt)	2017-12-12	composto, composição farmacêutica, e, uso de um composto
BR112013015397A2 (pt)	2016-09-20	composto, composição farmacêutica, e, uso de um composto
BRPI0614730A2 (pt)	2016-11-01	composto, composição farmacêutica, e, uso de um composto

Legal Events

Date	Code	Title	Description
2016-11-16	B25A	Requested transfer of rights approved	Owner name: IVAX INTERNATIONAL GMBH (CH)
2016-11-29	B25G	Requested change of headquarter approved	Owner name: IVAX INTERNATIONAL GMBH (CH)
2016-12-20	B25D	Requested change of name of applicant approved	Owner name: TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH)
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-02-05	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 11A ANUIDADE.
2019-04-16	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-05-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2509 DE 05-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.